- Home
- FGB vs CNTX Comparison
FGB vs CNTX Comparison
Compare FGB & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- CNTX
- Stock Information
- Founded
- FGB 2007
- CNTX 2015
- Country
- FGB United States
- CNTX United States
- Employees
- FGB N/A
- CNTX N/A
- Industry
- FGB Finance/Investors Services
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- FGB Finance
- CNTX Health Care
- Exchange
- FGB Nasdaq
- CNTX Nasdaq
- Market Cap
- FGB 60.1M
- CNTX 60.7M
- IPO Year
- FGB N/A
- CNTX 2021
- Fundamental
- Price
- FGB $3.88
- CNTX $0.78
- Analyst Decision
- FGB
- CNTX Strong Buy
- Analyst Count
- FGB 0
- CNTX 6
- Target Price
- FGB N/A
- CNTX $6.50
- AVG Volume (30 Days)
- FGB 53.0K
- CNTX 96.5K
- Earning Date
- FGB 01-01-0001
- CNTX 05-07-2025
- Dividend Yield
- FGB 8.92%
- CNTX N/A
- EPS Growth
- FGB N/A
- CNTX N/A
- EPS
- FGB N/A
- CNTX N/A
- Revenue
- FGB N/A
- CNTX N/A
- Revenue This Year
- FGB N/A
- CNTX N/A
- Revenue Next Year
- FGB N/A
- CNTX N/A
- P/E Ratio
- FGB N/A
- CNTX N/A
- Revenue Growth
- FGB N/A
- CNTX N/A
- 52 Week Low
- FGB $2.85
- CNTX $0.55
- 52 Week High
- FGB $3.74
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- FGB 47.05
- CNTX 44.94
- Support Level
- FGB $3.76
- CNTX $0.74
- Resistance Level
- FGB $3.87
- CNTX $0.85
- Average True Range (ATR)
- FGB 0.07
- CNTX 0.09
- MACD
- FGB 0.02
- CNTX -0.02
- Stochastic Oscillator
- FGB 68.00
- CNTX 13.30
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.